1-20 of 24
Fredrik H. Schjesvold
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status

Pieter Sonneveld, Maria-Victoria Mateos, Pawel J. Robak, Fredrik H. Schjesvold, Roman Hajek, Paul G. Richardson, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, Meletios-Athanasios Dimopoulos
Journal: Blood
Blood (2021) 138 (Supplement 1): 4779.
https://doi.org/10.1182/blood-2021-146844
Published: 2021
Journal Articles

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis

Meletios-Athanasios Dimopoulos, Fredrik H. Schjesvold, María-Victoria Mateos, Pawel J. Robak, Roman Hájek, Paul G. Richardson, Jakob Lindberg, Marcus Thuresson, Kajsa Larsson, Pieter Sonneveld
Journal: Blood
Blood (2021) 138 (Supplement 1): 4780.
https://doi.org/10.1182/blood-2021-146994
Published: 2021
Journal Articles

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Tadeusz Robak, Sosana Delimpasi, Ludek Pour, Tamas Masszi, Ivan Spicka, Wojciech Legiec, Pieter Sonneveld, Marcus Thuresson, Kajsa Larsson, Johan Harmenberg, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 4777.
https://doi.org/10.1182/blood-2021-146550
Published: 2021
Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses

Paul G. Richardson, Fredrik H. Schjesvold, Haifaa Abdulhaq, Daniel Coriu, Antonio Lazzaro, Pieter Sonneveld, Torbjörn Kullenburg, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, María-Victoria Mateos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2732.
https://doi.org/10.1182/blood-2021-146863
Published: 2021
Journal Articles

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Torben Plesner, Simon J Harrison, Hang Quach, Cindy H. Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Teiko Sumiyoshi, Karen Miller, Eunpi Choi, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 2755.
https://doi.org/10.1182/blood-2021-147418
Published: 2021
Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, Niels Abildgaard, Anna Lysén, Galina Tsykunova, Annette Juul Vangsted, Cristina João, Nora Remen, James P Connelly, Mona-Elisabeth R. Revheim, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 3939.
https://doi.org/10.1182/blood-2021-147240
Published: 2021
Journal Articles

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Joshua Richter, Jacob P. Laubach, Steve Stricker, Fredrik H. Schjesvold, David Cohan, Anna Sureda, Ewa Lech-Marańda, Meral Beksac, Vania Hungria, Meletios A. Dimopoulos, Ajai Chari, Paul G. Richardson, Philippe Moreau
Journal: Blood
Blood (2021) 138 (Supplement 1): 3759.
https://doi.org/10.1182/blood-2021-153694
Published: 2021
Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Niels W. C. J. Van De Donk, MD PhD, Bronno van der Holt, PhD, Fredrik H. Schjesvold, MD PhD, Ka Lung Wu, MD, Stefano Spada, Annemiek Broyl, MD PhD, Wilfried Roeloffzen, Alain Gaddiseur, Thomas Lund, MD, Monique C. Minnema, Massimo Offidani, Mariella Grasso, Niels Frost Andersen, Jo Caers, MD PhD, Benedetto Bruno, MD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Roman Hajek, Prof, MD PhD, Reuben Benjamin, MD, Francesca Gay, MD, Annette Juul Vangsted, MD PhD, Pellegrino Musto
Journal: Blood
Blood (2019) 134 (Supplement_1): 693.
https://doi.org/10.1182/blood-2019-125120
Published: 2019
Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Henrik Gregersen, MD PhD, Valdas Peceliunas, MD, Kari Remes, MD PhD, Fredrik H. Schjesvold, MD PhD, Niels Abildgaard, MD, Hareth Nahi, MD PhD, Niels Frost Andersen, MD PhD, Annette Juul Vangsted, MD PhD, Tobias Wirenfeldt Klausen, M.S., Carsten Helleberg, MD, Kristina Carlson, MD, Ulf Christian Frølund, MD, Per Axelsson, MD, Olga Stromberg, MD, Cecilie Hveding Blimark, PhD MD, Olle Linder, MD, Galina Tsykunova, MD, Anders Waage, MD PhD, Markus Hansson, MD PhD, Nina Gulbrandsen
Journal: Blood
Blood (2019) 134 (Supplement_1): 601.
https://doi.org/10.1182/blood-2019-122141
Published: 2019
Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen
Journal: Blood
Blood (2019) 134 (Supplement_1): 1893.
https://doi.org/10.1182/blood-2019-128010
Published: 2019
Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 926.
https://doi.org/10.1182/blood-2019-125871
Published: 2019
Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3163.
https://doi.org/10.1182/blood-2019-124244
Published: 2019
Journal Articles

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, MD, Niels Abildgaard, MD, Anna Lysén, MSc, Mona-Elisabeth R Revheim, MD PhD, James P Connelly, MD PhD, Fredrik H. Schjesvold, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3172.
https://doi.org/10.1182/blood-2019-125523
Published: 2019
Journal Articles

The Impact of RVD or VCD Induction on Response 3 Months after First Line Autologous Transplant in Multiple Myeloma. a Single-Center Retrospective Analysis

Magnus Moksnes, MD, Fredrik H. Schjesvold, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3445.
https://doi.org/10.1182/blood-2018-99-113270
Published: 2018
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, MDPhD, Fredrik H. Schjesvold, MDPhD, Bronno van der Holt, PhD, Mark-David Levin, MDPhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria B.L. Leijs, MD, Saskia K. Klein, MDPhD, Damian L. Szatkowski, MDPhDMSc, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MDPhD, Asta Svirskaite, Pino Poddighe, MDPhD, Marian Stevens-Kroef, MD, Markus Hansson, MD PhD, Niels WCJ van de Donk, MD PhD, Einar Haukas, MD, Pieter Sonneveld, MDPhD, Niels Abildgaard, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 800.
https://doi.org/10.1182/blood-2018-99-111650
Published: 2018
Journal Articles

In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy

Deepak Balaji balaji Thimiri Govinda Raj, PhD MSc, Andrea Cremaschi, PhD MSc, Sigrid Strand Skånland, PhD, Alexandra Gade, Fredrik H. Schjesvold, MD PhD, Geir Erland Tjønnfjord, MD DMsc, Ludvig A Munthe, Kjetil Tasken
Journal: Blood
Blood (2018) 132 (Supplement 1): 4676.
https://doi.org/10.1182/blood-2018-99-110357
Published: 2018
Journal Articles

Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy

Deepak Balaji balaji Thimiri Govinda Raj, PhD MSc, Mariaserena Giliberto, Andrea Cremaschi, PhD MSc, Sigrid Strand Skånland, PhD, Alexandra Gade, Geir Erland Tjønnfjord, MD DMsc, Fredrik H. Schjesvold, MD PhD, Ludvig Andre Munthe, MD PhD, Kjetil Tasken
Journal: Blood
Blood (2018) 132 (Supplement 1): 4677.
https://doi.org/10.1182/blood-2018-99-110669
Published: 2018
Journal Articles

Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway

Fredrik H. Schjesvold, MD PhD, Anderson Jenna, Jaak Sõnajalg, Amy Leval, PhD, Anna Lysén, MSc, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten
Journal: Blood
Blood (2018) 132 (Supplement 1): 5759.
https://doi.org/10.1182/blood-2018-99-114474
Published: 2018
Journal Articles

Carfilzomib-Based Regimens Are Efficacious and Well Tolerated in Heavily Pre-Treated Multiple Myeloma Patients: Real World Data from a Norwegian Cohort

Anna Lysén, MSc, Ina Haarstad, MDcal student, Fredrik H. Schjesvold, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5651.
https://doi.org/10.1182/blood-2018-99-110364
Published: 2018
Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Meletios A Dimopoulos, MD, Francesca Gay, MDPhD, Fredrik H. Schjesvold, MDPhD, Meral Beksac, MD, Roman Hajek, Katja Weisel, MD, Hartmut Goldschmidt, MD, Vladimir Maisnar, MD, Philippe Moreau, Chang-Ki Min, MD PhD, Agnieszka Pluta, MD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Martin Kaiser, MD, Sonja Zweegman, MDPhD, Maria-Victoria Mateos, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shinsuke Iida, MDPhD, Gareth Morgan, MD, Zhaoyang Teng, PhD, Kaveri Suryanarayan, MD, Tomas Skacel, MD PhD, Ajeeta B Dash, PhD, Richard Labotka, MD, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 301.
https://doi.org/10.1182/blood-2018-99-112079
Published: 2018